| Myasthenia Gravis |
ChiCTR-ORC-11001592: A comparison of dexmedetomidine versus flurbiprofen for analgesic effect in thymusectomy patients |
|
|
| Completed | 4 | 40 | | dexmedetomidine ;Flurbiprofen | urgical intensive care unit, The First Affiliated Hospital of Sun Yat-sen University University; Level of the institution：, research funding of SICU | myasthenic gravis with Thymusectomy | | | | |
2014-004344-35: The effect of tetanus revaccination in patients with myasthenia gravis Het effect of tetanus revaccinatie in patienten met myasthenia gravis. |
|
|
| Ongoing | 4 | 80 | Europe | Tetanus vaccin, Tetanus vaccin, Tetanus vaccin | Leiden University Medical Center, FP7 EU project nr 110173 | Myasthenia gravisLambert-Eaton myasthenic syndrome Myasthenia gravisLambert-Eaton myastheen syndroom | | | | |
2016-003138-26: Flu vaccine in patients with Myasthenia Gravis De griepprik in patienten met Myasthenia Gravis |
|
|
| Ongoing | 4 | 96 | Europe | Influenza vaccine, Suspension for injection, Influenza vaccine | LUMC, LUMC | Myasthenia gravis Myasthenia gravis, Myasthenia gravis Myasthenia gravis, Diseases [C] - Nervous System Diseases [C10] | | | | |
2017-002599-15: Effect of pyridostigmine (Mestinon®) on muscle strength in Myasthenia Gravis. |
|
|
| Ongoing | 4 | 32 | Europe | Capsule, Mestinon | Aarhus University, Aarhus University | Myasthenia Gravis, Myasthenia Gravis, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
ChiCTR-IPR-15006081: A prospective study of combined use of prednisone and methotrexate for the treatment of myasthenia gravis |
|
|
| Recruiting | 4 | 30 | | prednisone ;Prednisone + methotrexate | Xuan Wu Hospital, Capital Medical University; None, Xuan Wu Hospital, Capital Medical University | myasthenia gravis | | | | |
ChiCTR2000038863: Local Use of Dexamethasone in the Treatment of Ocular Myasthenia Gravis |
|
|
| Completed | 4 | 14 | | Local injection of hormone | Wuhan Aier Eye Hospital (Hanyang), Hubei, China; Wuhan Aier Eye Hospital (Hanyang), none | Ocular Myasthenia Gravis | | | | |
ChiCTR2000037904: Efficacy and safety of low-dose statins combined with conventional versus conventional treatment in patients with late onset myasthenia gravis: a prospective cohort study |
|
|
| Not yet recruiting | 4 | 20 | | statin | Qianfoshan Hospital; Qianfoshan Hospital, Academic Promotion Plan of Shandong First Medical University (No. : 2019QL013) | Myasthenia gravis | | | | |
ChiCTR1800018623: Different doses of methylprednisolone in the treatment of myasthenia gravis |
|
|
| Recruiting | 4 | 100 | | High dose hormone ;5 days hormone | The First Hospital of Shijiazhuang; The First Hospital of Shijiazhuang, self-raised | myasthenia gravis | | | | |
ChiCTR2200057193: Study on the dominant population of tacrolimus in the treatment of myasthenia gravis |
|
|
| Not yet recruiting | 4 | 100 | | Tacrolimus | Shijiazhuang People's Hospital; Shijiazhuang People's Hospital, Self-raised | myasthenia gravis | | | | |
ChiCTR2200066880: Clinical licensing application and a prospective, observational study of Efgartigimod Alfa Injection |
|
|
| Not yet recruiting | 4 | 20 | | On the basis of keeping the original myasthenia gravis treatment unchanged, the patients will be given Efgartigimod intravenous infusion (10mg/kg) once a week for 4 weeks | Hainan General Hospital; Hainan General Hospital, Zai Lab Limited | Generalised myasthenia gravis | | | | |
ChiCTR2200061488: Study on the mechanism of tacrolimus inhibiting B cell differentiation and development in the treatment of myasthenia gravis |
|
|
| Not yet recruiting | 4 | 20 | | Tacrolimus capsules, 2-3mg / day, bid | The Third Affiliated Hospital of Sun Yat-sen University; The Third Affiliated Hospital of Sun Yat-sen University, Hangzhou ZhongMei Huadong Pharmaceutical Co., Ltd. | myasthenia gravis (MG) | | | | |
2021-004110-20: Improving symptomatic treatment with pyridostigmine and amifampridine in patients with myasthenia gravis Verbeteren van de symptomatische behandeling met pyridostigmine en amifampridine bij patienten met myasthenia gravis. |
|
|
| Not yet recruiting | 3/4 | 24 | Europe | Amifampridine, Pyridostigmine, Tablet, Mestinon | Leiden University Medical Center, Leiden University Medical Center, NMD Pharma | Myasthenia Gravis Myasthenia Gravis, Myasthenia Gravis Myasthenia Gravis, Diseases [C] - Nervous System Diseases [C10] | | | | |
2018-000358-23: Study to evaluate the efficacy and safety of amifampridine phosphate drug in patients with Congenital Myasthenic Syndromes (CMS) Studio che valuta l'efficacia e la sicurezza del farmaco amifampridina fosfato in pazienti con Sindromi Miasteniche Congenite (SMC) |
|
|
| Not yet recruiting | 3 | 23 | Europe | Amifampridine phoshate, Tablet, FIRDAPSE - 10 MG - COMPRESSE - USO ORALE - BLISTER(ALU/PVC/PVDC) 100 X 1 COMPRESSE | CATALYST PHARMACEUTICALS INC., Catalyst Pharmaceuticals Inc. | Congenital myasthenic syndromes Sindromi miasteniche congenite, Congenital myasthenic syndromes Sindromi miasteniche congenite, Diseases [C] - Nervous System Diseases [C10] | | | | |
2019-000895-40: Beta-agonist Efficacy and Tolerability as Adjuvant therapy in Myasthenia Gravis |
|
|
| Not yet recruiting | 3 | 30 | Europe | Capsule, Salbutamol WZF 4 mg | Aarhus University Hospital, Aarhus University Hospital | Myasthenia Gravis, myasthenia gravis, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2018-002405-64: Clinical study evaluating the safety of amifampridine phosphate in patients with Congenital Myasthenic Syndromes (CMS) Studio clinico che valuta la sicurezza del farmaco amifampridina fosfato in pazienti con Sindromi Miasteniche Congenite (SMC) |
|
|
| Not yet recruiting | 3 | 20 | Europe | Amifampridina fosfato, [Amifampridina], Tablet, Firdapse | CATALYST PHARMACEUTICALS INC., CATALYST PHARMACEUTICALS INC. | Congenital Myasthenic Syndromes (CMS) Sindromi Miasteniche Congenite (SMC), Congenital Myasthenic Syndromes (CMS) Sindromi Miasteniche Congenite (SMC), Diseases [C] - Nervous System Diseases [C10] | | | | |
| Completed | 3 | 175 | Europe, Canada, Japan, US, RoW | Ravulizumab, ALXN1210, Ultomiris, Placebo | Alexion Pharmaceuticals, Inc. | Generalized Myasthenia Gravis | 05/21 | 05/23 | | |
2020-005619-35: SINGLE-CELL DEEP PHENOTYPING OF B LYMPHOCYTES TO PERSONALIZE IMMUNOTHERAPY IN PATIENTS WITH MYASTHENIA GRAVIS: CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF RITXUXIMAB IN GENERALIZED ACHR-ANTIBODY POSITIVE MYASTHENIA GRAVIS Fenotipizzazione dei linfociti B con studio della singola cellula per la personalizzazione dell’immunoterapia in pazienti con Miastenia Gravis: studio clinico randomizzato controllato contro placebo per valutare l’efficacia e la sicurezza del Rituximab in pazienti con Miastenia Gravis generalizzata associata ad anticorpi anti-recettore dell’Acetilcolina |
|
|
| Ongoing | 3 | 40 | Europe | rituximab, [rituximab], Concentrate for solution for infusion | FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE, Ministero della Salute | Generalized AChR-antibody positive Myasthenia Gravis Miastenia Gravis generalizzata associata ad anticorpi anti-recettore dell’Acetilcolina, generalized AChR-antibody positive Myasthenia Gravis Miastenia Gravis generalizzata associata ad anticorpi anti-recettore dell’Acetilcolina, Diseases [C] - Nervous System Diseases [C10] | | | | |
2020-004436-21: A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with Generalized Myasthenia Gravis |
|
|
| Ongoing | 3 | 240 | Europe | Satralizumab, RO5333787, Injection | F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd | Generalized Myasthenia Gravis (gMG), Myasthenia gravis is a rare neuromuscular disorder that causes weakness in the skeletal muscles. Myasthenia gravis affecting multiple muscle groups throughout the body is called gMG., Diseases [C] - Nervous System Diseases [C10] | | | | |
2020-005732-29: Efficacy and Safety Study of Nipocalimab IV Infusions for Adults With Generalized Myasthenia Gravis Estudio de eficacia y seguridad de las infusiones i.v. de nipocalimab para adultos con miastenia grave generalizada |
|
|
| Ongoing | 3 | 105 | Europe | Nipocalimab, JNJ-80202135, Solution for infusion | Janssen-Cilag International N.V., Janssen Research & Development, LLC | Myasthenia gravis (MG). Miastenia grave (MG), Myasthenia gravis, a neuromuscular disease. Miastenia grave, una enfermedad neuromuscular, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
NCT03759366 / 2016-001384-37: A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG) |
|
|
| Completed | 3 | 11 | Europe, Japan, US | Eculizumab | Alexion Pharmaceuticals, Inc. | Myasthenia Gravis, Myasthenia Gravis, Juvenile Form, Myasthenia Gravis, Generalized | 01/22 | 11/23 | | |
2021-003898-59: Efficacy and safety of tolebrutinib (SAR442168) tablets in adult participants with generalized myasthenia gravis Eficacia y seguridad de comprimidos de Tolebrutinib (SAR442168) en participantes adultos con miastenia gravis generalizada |
|
|
| Ongoing | 3 | 192 | Europe | Tolebrutininb, SAR442168, Film-coated tablet | Sanofi-Aventis Recherche & Développement, Sanofi-Aventis Recherche & Développement | Myasthenia gravis Miastenia gravis, Myasthenia gravis Miastenia gravis, Diseases [C] - Nervous System Diseases [C10] | | | | |
2018-002133-37: A safety and tolerability study of ARGX-113 in patients with myasthenia gravis who have generalized muscle weakness. |
|
|
| Not yet recruiting | 3 | 150 | Europe, RoW | Efgartigimod, ARGX-113, Concentrate for solution for infusion | argenx BVBA, ARGEN-X BVBA, argenx BVBA | Myasthenia Gravis, Myasthenia Gravis in patients who have generalized Muscle Weakness, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT05332587: Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis |
|
|
| Recruiting | 3 | 50 | RoW | Rituximab | First Affiliated Hospital, Sun Yat-Sen University | Refractory Myasthenia Gravis, Rituximab | 07/22 | 07/22 | | |
2021-000249-42: Phase 3 Study to Assess Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with gMG Studio di fase 3 per valutare l’efficacia e la sicurezza di Batoclimab come terapia di induzione e di mantenimento in partecipanti adulti affetti da miastenia grave generalizzata (gMG). |
|
|
| Not yet recruiting | 3 | 240 | Europe | Batoclimab, [IMVT-1401], Solution for injection in pre-filled syringe | Immunovant Sciences GmbH, Immunovant Sciences GmbH | Generalized Myasthenia Gravis (gMG) Miastenia grave generalizzata (gMG), Generalized Myasthenia Gravis (gMG) Miastenia grave generalizzata (gMG), Diseases [C] - Nervous System Diseases [C10] | | | | |
SCIG-MG, NCT02774239: A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation |
|
|
| Completed | 3 | 26 | Canada | Human normal immunoglobulin G (IgG), Hizentra® | University of Alberta, CSL Behring | Myasthenia Gravis | 10/22 | 10/22 | | |
MG, NCT05039190: Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized Patients |
|
|
| Completed | 3 | 132 | RoW | HBM9161 Injection (680mg), Placebo | Harbour BioMed (Guangzhou) Co. Ltd. | Myasthenia Gravis | 01/23 | 01/23 | | |
| Terminated | 3 | 6 | Europe, Canada, Japan, US, RoW | Tolebrutininb, Placebo | Sanofi, Sanofi-Aventis Recherche & Développement | Myasthenia Gravis | 02/23 | 02/23 | | |
| Terminated | 3 | 63 | Europe, US | Amifampridine Phosphate | Catalyst Pharmaceuticals, Inc. | Myasthenia Gravis, MuSK, AChR Myasthenia Gravis | 08/22 | 08/22 | | |
| Active, not recruiting | 3 | 69 | Europe, Canada, US, RoW | Efgartigimod concentrate for solution for infusion 20 mg/mL, Efgartigimod IV | argenx | Generalized Myasthenia Gravis | 08/23 | 05/26 | | |
NCT05332210: Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis |
|
|
| Recruiting | 3 | 144 | RoW | HBM9161 Injection (680mg) | Harbour BioMed (Guangzhou) Co. Ltd. | Myasthenia Gravis | 09/23 | 12/23 | | |
2022-000460-21: Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis. Seguridad y eficacia de ALXN1720 en adultos con miastenia gravis generalizada. |
|
|
| Not yet recruiting | 3 | 200 | Europe | Bexsero, na, Menveo, Ciprofloxacino normon 500mg, Eritromicina normon 500mg, Ciprofloxacina, Penilevel 500mg, ALXN1720, Concentrate for solution for injection, BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA PRERIEMPITA (VETRO) - 0.5ML - 1 SIRINGA PRERIEMPITA CON AGO, MENVEO - POLV.E SOLUZ.PER SOLUZ. INIETT.-USO INTRAMUSCOLARE-COMP. CONIUG.LIOFILIZZ.MENA:FLAC.(VETRO) COMP. GONIUG.LIQUI.MENCWY:FLAC.(VETRO)-1 FLAC+1FLAC, Menveo, Ciprofloxacino cinfa 500mg- cn 6970157, Ciprofloxacino normon 500mg -cn 6956212, Eritromicina normon 500mg – cn 6940167, Amoxicillina Almus 500, Bexsero, Ciprofloxacino teva 500mg – cn 6944967, Penilevel 500mg- cn 7135050 | Alexion Pharmaceuticals, Inc, ALEXION PHARMACEUTICALS INCORPORATED, Alexion Pharmaceuticals, Inc, Alexion Pharmaceuticals, Inc. | Generalized Myasthenia Gravis Miastenia Gravis Generalizada, Generalized Myasthenia Gravis Miastenia Gravis Generalizada, Diseases [C] - Nervous System Diseases [C10] | | | | |
ChiCTR2100050903: Multicenter, randomized, double-blind, placebo-controlled, phase 2/3 operational seamless, group sequential design study of the efficacy and safety of HBM9161 subcutaneous injection in patients with generalized myasthenia gravis |
|
|
| Not yet recruiting | 3 | 144 | | HBM9161 ;Placebo | Huashan Hospital Affiliated to Fudan University; Harbour BioMed (Suzhou) Co., Ltd., self-funded | Myasthenia Gravis | | | | |
| Recruiting | 3 | 198 | Europe, Canada, Japan, US, RoW | Nipocalimab, JNJ-80202135, M281, Placebo | Janssen Research & Development, LLC, Janssen Research & Development, LLC | Myasthenia Gravis | 11/23 | 04/26 | | |
| Completed | 3 | 165 | Europe, Canada, Japan, US, RoW | Rozanolixizumab, UCB7665 | UCB Biopharma SRL | Generalized Myasthenia Gravis | 01/24 | 01/24 | | |
NCT04963270 / 2020-004436-21: A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis |
|
|
| Active, not recruiting | 3 | 185 | Europe, Canada, Japan, US, RoW | Satralizumab, Placebo | Hoffmann-La Roche, Chugai Pharmaceutical | Generalized Myasthenia Gravis | 01/24 | 09/24 | | |
NCT05514873: An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors |
|
|
| Active, not recruiting | 3 | 26 | US | zilucoplan (RA101495) | UCB Biopharma SRL | Generalized Myasthenia Gravis | 03/24 | 11/24 | | |
NCT05403541: Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis |
|
|
| Recruiting | 3 | 240 | Europe, Canada, Japan, US, RoW | Batoclimab 680 mg SC weekly, IMVT-1401, Batoclimab 340 mg SC weekly, Matching Placebo SC, Batoclimab 340 mg SC bi-weekly | Immunovant Sciences GmbH | Generalized Myasthenia Gravis | 04/24 | 04/25 | | |
NCT06298552: A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis |
|
|
| Recruiting | 3 | 110 | US | Efgartigimod IV, Placebo IV | argenx | Generalized Myasthenia Gravis | 07/25 | 07/27 | | |
NCT05681715 / 2022-003870-21: A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG) |
|
|
| Completed | 3 | 62 | Europe, Canada, Japan, US, RoW | Rozanolixizumab | UCB Biopharma SRL, UCB Biopharma SRL | Generalized Myasthenia Gravis | 04/24 | 04/24 | | |
ChiCTR2200059452: A long-term open-label extension study to evaluate the safety of HBM9161 (HL161) subcutaneous injection in patients with generalized myasthenia gravis |
|
|
| Not yet recruiting | 3 | 144 | | HBM9161 680 mg was administered once a week (QW) ;HBM9161 340mg was administered 6 times per cycle for two cycles | Huashan Hospital Affiliated to Fudan University; Harbour BioMed (Suzhou) Co., Ltd., self-funded | Myasthenia gravis | | | | |
ARGX-113-2207, NCT06392386: A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis |
|
|
| Not yet recruiting | 3 | 12 | NA | Efgartigimod PH20 SC | argenx | Generalized Myasthenia Gravis | 09/26 | 09/26 | | |
IMCOMG, NCT06342544: Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial. |
|
|
| Not yet recruiting | 3 | 128 | NA | immediate treatment with corticosteroids, addition of rituximab if recurrence | Fondation Ophtalmologique Adolphe de Rothschild | Ocular Myasthenia Gravis | 06/28 | 06/29 | | |
NCT06456580: A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (RemeMG) |
|
|
| Not yet recruiting | 3 | 180 | NA | Telitacicept, RC18, RC18-L, Placebo | RemeGen Co., Ltd. | Generalized Myasthenia Gravis | 04/26 | 07/27 | | |
NCT06463587: Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad) |
|
|
| Recruiting | 3 | 240 | Japan | Placebo, Cladribine Low Dose, Cladribine High Dose | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc. | Generalized Myasthenia Gravis | 05/28 | 07/30 | | |
NCT06471361: A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis |
|
|
| Not yet recruiting | 3 | 25 | NA | Zilucoplan, RA101495 | UCB Biopharma SRL | Generalized Myasthenia Gravis | 12/24 | 12/24 | | |
ziMyG+, NCT06435312: An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis |
|
|
| Not yet recruiting | 3 | 8 | NA | Zilucoplan, RA101495 | UCB Biopharma SRL | Generalized Myasthenia Gravis | 10/27 | 12/27 | | |
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis |
|
|
| Recruiting | 3 | 235 | Europe, Canada, Japan, US, RoW | Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918 | Regeneron Pharmaceuticals | Generalized Myasthenia Gravis | 05/25 | 03/28 | | |
| Recruiting | 3 | 24 | Europe | Pyridostigmine, Amifampridine (base) with modified release, Placebo | Leiden University Medical Center, NMD Pharma A/S | Myasthenia Gravis | 09/24 | 09/24 | | |
| Active, not recruiting | 3 | 238 | Europe, Canada, Japan, US, RoW | inebilizumab, MEDI-551, VIB0551, IV Placebo | Amgen | Myasthenia Gravis | 05/24 | 11/27 | | |
| Active, not recruiting | 3 | 183 | Europe, Japan, US, RoW | efgartigimod PH20 SC | argenx | Generalized Myasthenia Gravis | 12/24 | 12/24 | | |
| Recruiting | 3 | 40 | Europe | Rituximab, MabThera, Rituxan, Placebo | Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Ministero della Salute | Myasthenia Gravis, Generalized | 07/25 | 07/25 | | |
NCT05556096: Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis |
|
|
| Recruiting | 3 | 254 | Europe, Canada, Japan, US, RoW | ALXN1720, Placebo | Alexion Pharmaceuticals, Inc. | Generalized Myasthenia Gravis | 08/25 | 07/27 | | |
| Active, not recruiting | 3 | 200 | Europe, Canada, Japan, US | zilucoplan (RA101495) | Ra Pharmaceuticals, Inc. | Generalized Myasthenia Gravis | 06/26 | 06/26 | | |
NCT05644561: Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG) |
|
|
| Recruiting | 3 | 12 | Europe, Japan, US, RoW | Ravulizumab | Alexion Pharmaceuticals, Inc. | Generalized Myasthenia Gravis, gMG | 07/26 | 07/28 | | |
NCT05737160: Study of Telitacicept in Generalized Myasthenia Gravis |
|
|
| Recruiting | 3 | 100 | RoW | Telitacicept, RC18, Placebo | RemeGen Co., Ltd. | Myasthenia Gravis, Generalized | 12/26 | 05/27 | | |
NCT04833894 / 2020-005841-18: Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis |
|
|
| Recruiting | 2/3 | 12 | Europe, Canada, US, RoW | Efgartigimod IV | argenx | Generalized Myasthenia Gravis | 08/24 | 08/24 | | |
roMyG, NCT06149559: A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis |
|
|
| Recruiting | 2/3 | 12 | Europe, US | rozanolixizumab, UCB7665 | UCB Biopharma SRL | Generalized Myasthenia Gravis | 06/26 | 08/26 | | |
SPH-B007-303, NCT06447597: A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers. |
|
|
| Not yet recruiting | 2/3 | 104 | RoW | B007, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Generalized Myasthenia Gravis | 06/26 | 06/26 | | |
tMG-E, NCT05716035: Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis |
|
|
| Recruiting | 2/3 | 64 | RoW | Tocilizumab Injection | Tang-Du Hospital | Myasthenia Gravis, Generalized | 07/24 | 12/24 | | |
| Recruiting | 2/3 | 12 | Europe, Japan, US | Nipocalimab, M281/JNJ-80202135 | Janssen Research & Development, LLC, Janssen Research & Development, LLC | Myasthenia Gravis | 03/25 | 12/25 | | |
NCT05374590 / 2021-002460-46: Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis |
|
|
| Recruiting | 2/3 | 12 | Europe, US | Efgartigimod IV or Efgartigimod PH20 SC | argenx | Generalized Myasthenia Gravis | 09/28 | 09/28 | | |
NCT06055959: A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis |
|
|
| Recruiting | 2/3 | 8 | Europe, US, RoW | Zilucoplan, RA101495 | UCB Biopharma SRL | Generalized Myasthenia Gravis | 10/26 | 12/26 | | |
| Not yet recruiting | 2 | 20 | | | St Vincent's Hospital, Sydney , St Vincent's Hospital,Sydney | Neuromyelitis Optica, Stiff Person Syndrome, Myasthenia Gravis, Central Nervous System Vasculitis | | | | |
2014-001355-23: Ephedrine as add-on therapy for patients with myasthenia gravis Efedrine als toegevoegde behandeling voor patiënten met myastheniagravis |
|
|
| Ongoing | 2 | 4 | Europe | Tablet, Hidrocloruro de efedrina (In English: Ephedrine HCl) | Leiden University Medical Center, ZonMw | myasthenia gravis myasthenia gravis, myasthenia myasthenie, Diseases [C] - Nervous System Diseases [C10] | | | | |
2015-003127-62: A Randomized, Placebo-Controlled Study to Evaluate the Effect of Amifampridine in Patients with MuSK Antibody Positive Myasthenia Gravis Studio randomizzato controllato con placebo per valutare l'effetto dell'amifampridina in pazienti affetti da Miastenia Grave Musk positivi |
|
|
| Ongoing | 2 | 20 | Europe | AMIFAMPRIDINA, Tablet, FIRDAPSE - 10 MG - COMPRESSE - USO ORALE - BLISTER(ALU/PVC/PVDC) 100 X 1 COMPRESSE | FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA, Catalyst Pharmaceutical Partners, Inc. | Patients with MuSK Antibody Positive Myasthenia Gravis Pazienti affetti da Miastenia Grave MuSK-positiva, Patients with MuSK Antibody Positive Myasthenia Gravis Pazienti affetti da Miastenia Grave MuSK-positiva, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
|
2005-002740-26: A Phase II Double Blind, Cross-Over Study to Compare the Safety and Efficacy of 10, 20 and 40 mg Monarsen (EN101) administered to Patients with Myasthenia Gravis |
|
|
| Ongoing | 2 | 15 | Europe | MONARSEN, EN101, | Ester Neuroscience Ltd | Myasthenia Gravis | | | | |
2007-002817-37: A PHASE II, PLACEBO CONTROLLED, DOSE FINDING PILOT STUDY OF PIXANTRONE EFFICACY ADMINISTERED INTRAVENOUSLY IN PATIENTS AFFECTED WITH MYASTHENIA GRAVIS |
|
|
| Ongoing | 2 | 20 | Europe | PIXANTRONE, BBR 2778, | ISTITUTO NEUROLOGICO \"CARLO BESTA\" | Patients affected with MG showing clinically meaningful improvement after therapeutic plasmapheresis. | | | | |
2012-001544-21: Intravenous immunoglobulin for preparing myasthenia gravis patients for thymectomy and other surgical procedures preventing myasthenic crisis. Inmunoglobulina intravenosa para la prevención de crisis miasténica en pacientes con Miastenia Gravis antes de la timectomÃa y en la preparación de otros procedimientos quirúrgicos |
|
|
| Ongoing | 2 | 84 | Europe | PRIVIGEN, PRIVIGEN | Vall d\'Hebron Institut de Recerca (VHIR), VHIR | Myasthenia gravis Miastenia gravis | | | | |
NCT02093624: A Phase II Trial of Rituximab In Myasthenia Gravis |
|
|
| Not yet recruiting | 2 | 50 | US | Rituximab, Placebo | Yale University | Myasthenia Gravis | 05/17 | 12/17 | | |
| Not yet recruiting | 2 | 200 | Europe | Cladrybine, Solution for injection | Medical University of Lublin, Medical University of Lublin | Myasthenia gravis, Myasthenia gravis is an autoimmune disease manifesting itself inincreasing post-stress weakness of the muscles of the eyes, mouth,throat and limbs, with periods of life-threatening exacerbations, Diseases [C] - Immune System Diseases [C20] | | | | |
| Not yet recruiting | 2 | 30 | | HBM9161 dose 1 ;HBM9161 dose 2 ;Placebo | Huashan Hospital Affiliated to Fudan University; Harbour BioMed (Suzhou) Co., Ltd, Harbour BioMed (Guangzhou) Co., Ltd | Myasthenia Gravis | | | | |
NCT04302103: A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis |
|
|
| Completed | 2 | 29 | RoW | RC18 160mg, RC18 240 mg | RemeGen Co., Ltd. | Systemic Myasthenia Gravis | 01/22 | 02/22 | | |
NCT04226170: Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis |
|
|
| Recruiting | 2 | 24 | US | DAS-001 | DAS-MG, Inc | Myasthenia Gravis | 04/23 | 04/23 | | |
| Recruiting | 2 | 30 | Canada | subcutaneous immunoglobulin (SCIG), Cuvitru, intravenous immunoglobulin + subcutaneous immunoglobulin (SCIG), Gammanorm + Cuvitru | University Health Network, Toronto | Myasthenia Gravis | 06/23 | 12/23 | | |
| Terminated | 2 | 70 | Europe, Canada, US, RoW | ALXN2050, ACH-0145228 (formerly), Placebo | Alexion Pharmaceuticals, Inc. | Generalized Myasthenia Gravis, Myasthenia Gravis | 11/23 | 04/24 | | |
NCT04146051: Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) |
|
|
| Recruiting | 2 | 30 | Canada, US | Descartes-08 | Cartesian Therapeutics | Myasthenia Gravis, Generalized | 03/25 | 03/26 | | |
NCT06221501: Perioperative Efgartigimod for Thymoma and Myasthenia Gravis |
|
|
| Not yet recruiting | 2 | 30 | NA | Efgartigimod Alfa | Shanghai Zhongshan Hospital | Myasthenia Gravis | 12/26 | 06/27 | | |
MAGIC, NCT06282159: A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis |
|
|
| Recruiting | 2 | 60 | US | DNTH103, Placebo | Dianthus Therapeutics | Myasthenia Gravis, Generalized | 12/25 | 12/27 | | |
NCT06193889: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Refractory Generalized Myasthenia Gravis |
|
|
| Not yet recruiting | 2 | 20 | NA | KYV-101, Standard lymphodepletion regimen, Cyclophosphamide, Fludarabine | Kyverna Therapeutics | Myasthenia Gravis, Generalized Myasthenia Gravis | 05/26 | 05/27 | | |
tMG, NCT05067348: Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis |
|
|
| Recruiting | 2 | 64 | RoW | Tocilizumab Injectable Product | Tang-Du Hospital | Myasthenia Gravis, Generalized | 03/24 | 09/24 | | |
| Recruiting | 2 | 84 | US | NMD670, Placebo | NMD Pharma A/S | Myasthenia Gravis, Myasthenia Gravis, MuSK | 11/25 | 11/25 | | |
3-Hole, NCT02317224: The Safety and Efficacy of "" Subxiphorid Approach in the Treatment of Anterior Mediastinal Tumor |
|
|
| Recruiting | 2 | 240 | RoW | "3-Hole" subxiphorid and subcostal approach, 3-Hole approach, Trans sternal approach, median sternotomy, VATS approach, Video-assisted thoracoscope | Tang-Du Hospital | Thymectomy, Myasthenia Gravis | 12/24 | 12/24 | | |
NCT00716066: Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases |
|
|
| Active, not recruiting | 2 | 53 | US | Anti-Thymocyte Globulin, Antithymocyte Globulin, Antithymocyte Serum, ATG, ATGAM, ATS, Thymoglobulin, Autologous Hematopoietic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Carmustine, BCNU, Becenum, Becenun, BiCNU, Bis(chloroethyl) Nitrosourea, Bis-Chloronitrosourea, Carmubris, Carmustin, Carmustinum, FDA 0345, Gliadel, N,N'-Bis(2-chloroethyl)-N-nitrosourea, Nitrourean, Nitrumon, SK 27702, SRI 1720, WR-139021, 154-93-8, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, 147-94-4, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, 33419-42-0, Laboratory Biomarker Analysis, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, 148-82-3, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, Peripheral Blood Progenitor Cell Transplantation, Peripheral Stem Cell Support, Peripheral Stem Cell Transplantation, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone, 53-03-2, Syngeneic Bone Marrow Transplantation | Fred Hutchinson Cancer Center | Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune, Multiple Sclerosis Transplant, MS Stem Cell Transplant, Multiple Sclerosis Stem Cell Transplant, Stiff Person Syndrome, HCT for Neurologic Autoimmune Disorders, CIDP Transplant, Myasthenia Gravis Transplant, Autoimmune Nervous System Disorder, Central Nervous System Vasculitis, Cerebellar Degeneration, Chronic Inflammatory Demyelinating Polyneuropathy, Lambert Eaton Myasthenic Syndrome, Myasthenia Gravis, Neuromyelitis Optica, Opsoclonus Myoclonus Syndrome, Rasmussen Subacute Encephalitis | 01/25 | 01/30 | | |
ChiCTR-TRC-13004125: The study on the pathogenesis of spleen-kidney deficiency type myasthenia gravis and the interference effect of Jianji Ning Granule on the patients |
|
|
| Completed | 1/2 | 60 | | Jianji Ning Granule combined with olfactory pyridostigmine tablets ;olfactory pyridostigmine tablets | Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine ; Level of the institution：, Shanghai Science and Technology Commission | Myasthenia gravis | | | | |
CAB-201-004, NCT06359041: RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis |
|
|
| Recruiting | 1/2 | 12 | US | CABA-201 | Cabaletta Bio | Generalized Myasthenia Gravis (gMG) | 09/29 | 09/29 | | |
NCT06106672: Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis |
|
|
| Recruiting | 1/2 | 54 | US | CNP-106, Placebo | COUR Pharmaceutical Development Company, Inc. | Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis, MuSK MG | 06/26 | 08/26 | | |
ACTRN12624000545561: Safety and efficacy studies of neostigmine administration as a topical ophthalmic solution for diagnosing ocular myasthenia gravis in adults presenting with ptosis |
|
|
| Not yet recruiting | 1 | 24 | | | Faculty of Medicine, Chulalongkorn University, Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University | Myasthenia gravis | | | | |
NCT04431895: Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study |
|
|
| Recruiting | 1 | 20 | RoW | Tofacitinib 5 MG | Huashan Hospital | Myasthenia Gravis, Generalized | 02/23 | 02/23 | | |
| Not yet recruiting | 1 | 12 | US | Oxaloacetate, CRONaxal, Placebo | University of Kansas Medical Center, Terra Biological LLC | Myasthenia Gravis | 04/23 | 04/23 | | |
| Not yet recruiting | 1 | 100 | | N/A | The Second Affiliated Hospital of Dalian Medical University; 辽宁省大连市沙河口区星海湾街道中山路467号大连医科大学附属第二医院C座, None | Myasthenia Gravis | | | | |
CARTinNS, NCT04561557: Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System |
|
|
| Recruiting | 1 | 36 | RoW | CT103A cells, Cyclophosphamide and fludarabine | Tongji Hospital, Nanjing IASO Biotechnology Co., Ltd. | Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Idiopathic Inflammatory Myopathies, Multiple Sclerosis, Autoimmune Encephalitis, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), POEMS Syndrome | 02/27 | 05/27 | | |
NCT06371040: Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis |
|
|
| Not yet recruiting | 1 | 12 | RoW | CD19-BCMA Targeted CAR-T Dose 1, CD19-BCMA Targeted CAR-T Dose 2 | Ting Chang, MD | Myasthenia Gravis | 03/25 | 12/26 | | |
NCT06436742: A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS) |
|
|
| Not yet recruiting | 1 | 15 | NA | ARGX-119, Placebo | argenx | Congenital Myasthenic Syndrome | 10/25 | 10/25 | | |
NCT06419166: An Exploratory Clinical Study of GC012F Injection for the Treatment of Refractory Generalized Myasthenia Gravis |
|
|
| Recruiting | 1 | 18 | RoW | GC012F injection | Zhejiang University, Gracell Biotechnology Shanghai Co., Ltd. | Refractory Generalized Myasthenia Gravis | 06/26 | 10/26 | | |
NCT05828225: Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of Refractory Myasthenia Gravis |
|
|
| Recruiting | 1 | 9 | RoW | CD19 CAR-T cells injection | Zhejiang University | Myasthenia Gravis | 04/26 | 04/26 | | |
NCT05451212: Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis |
|
|
| Recruiting | 1 | 24 | US | MuSK-CAART | Cabaletta Bio | MuSK Myasthenia Gravis | 10/28 | 10/28 | | |
ChiCTR2200057039: Research on the development of a new Chinese medicine for treating myasthenia gravis |
|
|
| Not yet recruiting | N/A | 200 | | Fufang Huangqi preparation ;None ;None | Affiliated Hospital of Liaoning University of Traditional Chinese Medicine; Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Science and Technology Department of Liaoning Province | Myasthenia gravis | | | | |
ChiCTR-TRC-12003062: multi-center, Double-blind Randomized controlled trials of Chinese medicine to treatment myasthenia gravis patients |
|
|
| Completed | N/A | 230 | | Western medicine and Chinese medicines granules ;Western medicine and Chinese medicines granules placebo | Guangzhou University of TCM; Ministry of National Science and Technology, National Science and technology supporting project | Myasthenia gravis | | | | |
NCT01373333: Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome |
|
|
| No Longer Available | N/A | | US | 3,4 DAP | The Cleveland Clinic | Lambert-Eaton Myasthenic Syndrome | 09/12 | | | |
ChiCTR-OCC-13003090: Research on micrornas expression of Myasthenia gravis and the relationship with TH1, TH2 cells secrete cytokines |
|
|
| Completed | N/A | 60 | | Pyridostigmine Bromide ;nothing | The first affiliated hospital of Guangzhou university of Traditional Chinese medicine; The first affiliated hospital of Guangzhou university of Traditional Chinese medicine, National key disciplines fee | Myasthenia gravis | | | | |